Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
These gynecologic cancers share molecular characteristics and often arise from serous cell types. DNA repair biomarkers play a central role in treatment selection.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| FOLR1 |
|
Defined at the solid tumor level and applicable to Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Select a therapy to view the specific approval and eligible tests.
FOLR1 (protein expression)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)